Replies to post #126727 on Biotech Values

[ghmm]

I was suprised when I saw that as well. I can't imagine they paid too much for it since the company was in bankrupcy. I wonder if Merck KG just took a feeler on the program since its not costing them much as an avenue for a potential "BioBetter" of Copaxone?

[DewDiligence]

Yet another clueless blog from Seeking Alpha:

http://seekingalpha.com/article/294659-merck-s-curious-ms-acquisition-was-a-gamble-worth-taking

Merck's Curious MS Acquisition Was A Gamble Worth Taking

The odds may be extremely long, but when the wager is just $1.5m for a phase II-ready product in a major therapeutic area, it may just be worth a flutter. That could be the thinking behind Merck KGaA’s (MRK) decision to acquire PI-2301 from the bankrupt debris of Peptimmune…

Merck KGaA is not MRK. LMAO